-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N6gCKsxpLdjzXgvESMjTl7oGWoIfF4frKOqedytQ1tOU/GD8+cnzkCPtBl+DeH+R oQYnwtivA5gTd486Lb1B3Q== 0000893220-08-000316.txt : 20080212 0000893220-08-000316.hdr.sgml : 20080212 20080212144847 ACCESSION NUMBER: 0000893220-08-000316 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080212 DATE AS OF CHANGE: 20080212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CYTOKINETICS INC CENTRAL INDEX KEY: 0001061983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943291317 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79858 FILM NUMBER: 08597730 BUSINESS ADDRESS: STREET 1: 280 EAST GRAND AVENUE STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 624-3000 MAIL ADDRESS: STREET 1: 280 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS SC 13G/A 1 w48539sc13gza.htm SCHEDULE 13G, AMENDMENT NO. 2, CYTOKINETICS, INCORPORATED sc13gza
 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
CYTOKINETICS, INCORPORATED
(Name of Issuer)
Common Stock
 
(Title of Class of Securities)
23282W100
 
(CUSIP Number)
December 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the following box to designate the rule pursuant to which this Schedule is filed:
           o   Rule 13d-1(b)
           o   Rule 13d-1(c)
           þ   Rule 13d-1(d)
*The remainder of this cover page shall be filled our for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
This Amendment No. 1 amends and supplements the Statement on Schedule 13G electronically filed with the Securities and Exchange Commission (the “Commission”) on May 20, 2004 with respect of the ownership of securities of Cytokinetics, Incorporated (the “Initial Statement”). Since reporting person now holds less than 5% with this filing, further reporting under Schedule 13G is no longer required.
The undersigned hereby amends and supplements Item 5 of the Initial Statement with the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement).
(Continued on following page(s))

 

 

     
                     
CUSIP No.
  
23282W100 
13G 
  

 

           
1   NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GlaxoSmithKline plc
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
  (a)   o
  (b)   o
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  England and Wales
       
  5   SOLE VOTING POWER
     
NUMBER OF   2,042,610
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   -0-
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   2,042,610
       
WITH 8   SHARED DISPOSITIVE POWER
     
    -0-
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  2,042,610
     
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
   
  4.2%
     
12   TYPE OF REPORTING PERSON*
   
  CO
*SEE INSTRUCTION BEFORE FILLING OUT!

 

 

 

CUSIP NO. 23282W100
         
Item 1.
  (a).   Name of Issuer:
 
        
 
  (b).   Address of Issuer’s Principal Executive Offices:
 
        
Item 2.
  (a).   Names of Person Filing:
 
        
 
  (b).   Address of Principal Business Office:
 
        
 
  (c).   Citizenship:
 
        
 
  (d).   Title of Class of Securities:
 
        
 
  (e).   CUSIP Number:
 
        
Item 3.
      Not Applicable.
 
        
Item 4.
      Ownership.
 
        
 
      The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.
 
        
Item 5.
      Ownership of Five Percent or Less of a Class:

 

 

         
 
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].
 
        
Item 6.
      Ownership of More Than Five Percent on Behalf of Another
 
      Person:
 
        
Item 7.
      Identification and Classification of Subsidiaries Which
 
      Acquired the Security Being Reported on by the Parent
Holding Company:
 
        
Item 8.
      Identification and Classification of Members of the Group:
 
        
Item 9.
      Notice of Dissolution of Group:
 
        
Item 10.
      Certification:
 
        
 
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.
 
        
 
      Signature:
 
        
 
      After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
  GLAXOSMITHKLINE PLC
 		  
  By:   /s/    
    Victoria A. Whyte   
    Deputy Secretary   
 
Dated: February 11, 2008

 

-----END PRIVACY-ENHANCED MESSAGE-----